Cutanos Wins BARDA VITAL Prize Challenge for Innovative Vaccine Technology!
Vienna, Austria (July 1, 2024) – Cutanos GmbH, a biotechnology company based in Vienna, Austria, was awarded first place in the BARDA VITAL Prize (BVP) Challenge, endowed with USD 20,000 by the BARDA Accelerator Network (BAN), at the BARDA VITAL Symposium in Berlin, Germany. Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network (BAN) fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions. The BARDA VITAL Prize Challenge awards innovative startups and their groundbreaking solutions to potentially make a significant impact on public health.
Cutanos is dedicated to developing next-generation vaccines incorporating its proprietary Langerhans Cell Targeting (LC-TDS) Technology. Looking ahead, the company will increase its efforts towards infectious diseases, capitalizing on the advantages of its technology to boost the efficacy and stability of mRNA vaccines as well as high patient compliance due to pain-free skin administration.
„We are incredibly honored to receive this recognition from BARDA,“ said Robert Wawrzinek, CEO of Cutanos. „This award validates our commitment to develop innovative vaccine technologies that can make a real difference in the fight against infectious diseases. We believe that minimally invasive vaccination will improve vaccine acceptance and accessibility worldwide.“
More information:
BARDA Vital Prize: https://vitalhubhealth.com/prize-challenge/
Photo above by VITALHub